期刊文献+

大剂量谷胱甘肽加维生素C对特发性肺纤维化的疗效观察 被引量:2

A study of curative effects of big dose GSH and vitamin C to idiopathic pulmonary fibrosis
原文传递
导出
摘要 目的 观察大剂量还原型谷胱甘肽(GSH)和维生素C对特发性肺纤维化(IPF)的疗效.探讨其可能的作用机制和治疗价值。方法 18例临床诊断IPF患者以GSH2.4g和维生素C4.0g静注,1次/d.1个月后,以GSH0.3g维生素C0.5g,每日2次雾化吸入维持治疗.统计1个月内的症状改变情况.1个月前后1min步行距离及步行1minPaO,、SaO,值的变化及4年内患者生存情况。结果(1)患者在治疗第2、4周末总体症状好转率分别为89%和94%,两者差异无统计学意义(P〉0.05)。(2)治疗前轻症组和重症组1min步行距离分别为(40.5±5.8)m和(25.8±3.8)m,治疗1个月分别为(58.5±4.2)m和(42.5±4.1)m,两组前后比较差异均有统计学意义(P〈0.01)。(3)轻症组治疗前.步行1minPaO2和SaO2值分别为(65.3±4.9)mmHg和(90.5±6.1)%,1个月后分别为(75.2±5.2)mmHg、(95.0±3.2)%,前后对比差异有统计学意义(P〈O.01)。重症组治疗前步行1minPa02和Sa()’值分别为(48.2±4.8)mmHg和(75.5±5.2)%,治疗1个月后分别为(51.5±5.3)mmHg和(78.3±5.1)%.前后对比差异无统计学意义(均P〉0.05)。(4)4年内18例患者生存情况显示,轻症组预后较好。重症组预后不良.死亡6例,占总数60%,中位死亡时间为2.2年。结论 大剂量GSH和维生素C治疗IPF有效,雾化吸入法可维持疗效;对早期渗出性病变疗效好,但不能阻止重症患者肺纤维化的进程。 Objective To study the curative effects of big dose GSH and vitamin C to idiopathic pulmonary fibrosis(1PF). Methods Big dose GSH and vitamin C intravenous were injected to 18 cases IPF who were of no effects to corticoid for a month,pulverization inhale GSH and vitamin C in the following days for constant therapy. The improvement of patients' syndromes,record distance of one minute walking,and PaO2,SaO2 after a minute walking were recorded, the datas before-and-after one month treatment were compared, these patients survive state in 4 years were recorded and the computation datas by statistics methods were compared,the validity of this method was primarily evaluated. Results (1)There were 89 % and 94 % of patients' common syndromes had been improved in 2 and 4 weeks,cough was the first improved syndrome. Postpone this treatment did not promote the rate of improvement. This method could improve the syndromes of IPF rapidly and notably. (2)Before the treatment, one minute walking distance of the slightly group and heavy group was (40.5 ± 5.8) meters and (25.8 ± 3.8) meters each. One month later after the treatment,the distance was (58.5 ± 4.2) and (42.5 ± 4.2) meters for each group. The data of before and after the treatment had significant difference by pared t test, P 〈 0.01, pulmonary function and kinematical function had been notably improved. (3)Before treatment, the slightly groups PaO2 and SaO2 after one minute walking was (51.3 ± 4.9) mmHg and (70.5 ± 6.1 ) % ,later after 30 days therapy, data become (48.5 ± 5.3) mmHg and (65.3 ± 5. 1 ) % , and there was significant difference between these two data, P 〈 0.01. For heavy group, PaO2 and SaO2 after one minute walking before and after treatment was respectively (45.2 ± 4.8)mmHg, (60.5 ± 5.2)96 ,and (48.5 ± 5.3)mmHg and (65.3 ± 5.1 ) % . the data before and after treatment had no significant difference(P 〉 0.05). It showed that this method could improve syndromes and kinematical function of slight group, and it could only improve common syndromes of heavy illness group, but did not improve PaO2 and SaO2 of heavy group. (4)Survival state of 18 IPF patients in 4 years: the statistics showed that the slightly group had good predication by the GSH and vitamin C treatment, but for the heavy group the prediction was still worse. It refered to hint that it was very important to diagnose and cure IPF early. Conclusions Big dose GSH and vitamin C have good effects to IPF patiects,eapecially to the early stage IPF. Although GSH and vitamin C may eliminate the effusion in- flammation, but may not prevent the process of lung fibrosis.
出处 《中国基层医药》 CAS 2007年第6期884-886,I0001,共4页 Chinese Journal of Primary Medicine and Pharmacy
关键词 谷胱甘肽 抗坏血酸 肺纤维化 Glutathione Ascorbic acid Pulmonary fibrosis
  • 相关文献

参考文献7

  • 1American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med,2002,165(2) :277-304.
  • 2Luppi F, Cerri S, Beghe B, et al. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir Med, 2004, 98 (11) : 1035-1044.
  • 3Collard RyuJH DouglasWW etal 刘燔译 康健校.皮质类固醇和环磷酰胺联合治疗不能改变特发性肺纤维化患者的生存时间[J].Chest(中文版),2004,1(6):486-491.
  • 4Raghu G, Chang J. Idiopathic pulmonary fibrosis: current trends in management. Clin Chest Med,2004,25(4) :621-636.
  • 5崔德健.特发性间质性肺炎[J].中华内科杂志,2006,45(8):679-683. 被引量:4
  • 6柴文戍,李永春,李艳勤,徐蔼丽.谷胱甘肽对大鼠肺纤维化模型的干预作用[J].中国医师杂志,2003,5(3):295-297. 被引量:10
  • 7Pela R, Calcagni AM, Subiaco S, et al. N-Acetyclysteinereduces the exacerbation rate in patients with moderate to severe COPD. Respiration, 1999,66(6) :495-500.

二级参考文献24

  • 1孔琪,秦川.肺纤维化的发病机制及关键靶点[J].国外医学(呼吸系统分册),2005,25(5):331-333. 被引量:34
  • 2张彦萍,曹书颖.PAI-1与肺纤维化[J].国外医学(呼吸系统分册),2005,25(5):343-344. 被引量:5
  • 3庄谊,张德平.肺纤维化与Th1/Th2失衡[J].国外医学(呼吸系统分册),2005,25(5):349-351. 被引量:17
  • 4谷丽,朱元珏.特发性肺间质纤维化与肺肌成纤维细胞[J].国外医学(呼吸系统分册),2005,25(5):361-363. 被引量:18
  • 5马跃文,王宏达,李振华.特发性肺纤维化患者支气管肺泡灌洗液谷胱甘肽和透明质酸的检测[J].中国实用内科杂志,1997,17(4):205-206. 被引量:3
  • 6American Thoracic Society; European Respiratory Society.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.This joint statement of the American Thoracic Society(ATS),and the European Respiratory Society (ERS) was adopted by the ATS board of directors,June 2001 and by the ERS Executive Committee,June 2001.Am J Respir Crit Care Med,2002,165:277-304.
  • 7Coultas DB,Zumwalt RE,Black WC,et al.The epidemiology of interstitial lung diseases.Am J Respir Crit Care Med,1994,150:967-972.
  • 8Noble PW,Homer RJ.Idiopathic pulmonary fibrosis:new insights into pathogenesis.Clin Chest Med,2004,25:749-758.
  • 9Johnston ID,Prescott BJ,Chalmers JC,et al.British Thoracic Society study of cryptogenic fibrosing alveolitis:current presentation and initial management.Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.Thorax,1997,52:38-44.
  • 10Selman M,King TE,Pardo A,et al.Idiopathic pulmonary fibrosis:prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med,2001,134:136-151.

共引文献13

同被引文献11

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部